Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Sitagliptin for HIV Insulin Resistance and Inflammation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-65 yr old HIV infected men and women.~* Stable (at least the past 6 months) on combined antiretroviral therapy (cART).~* Stable immune (\> 300 CD4+ T-cells/µL) and virologic (\< 50 copies HIV RNA/mL) status.~* Insulin resistant/impaired glucose tolerance (fasting glucose 100-125mg/dL, or 2-hr glucose 140-200mg/dL or fasting HOMA-IR= 2.5-6.0).~* Waist circumference \> 102 cm (men), \> 88 cm (women).~* BMI \> 20 kg/m2.~* Fasting hypertriglyceridemia \> 150 mg/dL.~* Low HDL-cholesterol (\< 40 mg/dL in men or \< 50 mg/dL in women).~* Platelet count \> 30,000/mm3.~* Absolute neutrophil count \> 750/mm3.~* Transaminases \< 2.5x the upper limit of normal.~* Long-term non-progressors (not taking anti-HIV medications) are not eligible.~Exclusion Criteria:~* Diabetes (T2DM, IDDM or diabetic ketoacidosis) or taking any glucose-lowering medication (e.g., insulin, TZDs, metformin, sulfonylurea).~* Any agent that might artifactually alter glycemic control (e.g., glucocorticoids, megace, rhGH, GH-secretagogue, testosterone derivatives, creatine monohydrate, chromium picolinate, AA/protein supplements, medium- or long-chain fatty acids) during 6 months prior to or during enrollment.~* History of serious CV disease. NYHA Functional Class III or IV (e.g., recent MI, unstable angina, edema, CHF, CAD, CABG, stroke, resting hypertension \> 160/95 mmHg), irregular heart rhythm, resting ST-segment depression \> 1mm). Treatment with medications for CV condition (e.g., α- or ß-blockers). Some BP-lowering medications (Ca++channel blocker, diuretic, or ACE inhibitor) are permitted.~* Moderate to severe renal insufficiency. Serum creatinine \> 1.7 mg/dL (men) \> 1.5 mg/dL (women).~* Plan or anticipate a change in anti-HIV medications during the study.~* Lipid-lowering medications are permitted (fibrate or statin or niacin), but must be stable on that agent for at least 6 months prior to enrollment. Lipid-lowering agents cannot be started during the treatment period.~* Chronic hepatitis B (HBV-surface antigen positive). Active hepatitis C (detectable Hep C RNA).~* Positive urine drug test for opiates, methamphetamine, heroin, cocaine. Active substance abuse that the MD-scientist believes may compromise safety, compliance, interfere with study drug or data interpretation.~* Hematocrit \< 34% in men or \< 25% in women with symptoms (fatigue, tired-legs, shortness of breath). Hemoglobin \< 10 gm/dL with symptoms.~* Pregnant or nursing mothers. Women must agree to use an acceptable form of birth control during the study. If using birth control pills-must be stable on this medication for at least 6 months prior to enrollment.~* Active malignancy or treatment with chemotherapeutic agents or radiation therapy or any cytokine or anti-cytokine therapy during 6 months prior to enrollment.~* History of pancreatitis~* \> 10% unintentional weight loss during the 6 months prior to enrollment.~* Reduced cognitive function/unable to provide voluntary informed consent. Prisoners are excluded.~* Blinded investigational drugs for 3 months prior to enrollment that will not be unblinded before enrollment.~* Nausea, vomiting, diarrhea (\> 4 loose stools/day) that are unresponsive to treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: EXPERIMENTAL): 100 mg sitagliptin/day for 2 months
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo daily for 2 months

Based on this trial design, predict the completion outcome and termination type (if applicable).